Jane Street Group LLC Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Jane Street Group LLC acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 12,151 shares of the company’s stock, valued at approximately $309,000.

A number of other institutional investors also recently made changes to their positions in BCAX. Wellington Management Group LLP acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $19,458,000. Soros Fund Management LLC acquired a new position in Bicara Therapeutics during the 3rd quarter worth approximately $509,000. Samsara BioCapital LLC bought a new position in shares of Bicara Therapeutics in the 3rd quarter valued at $891,000. RA Capital Management L.P. bought a new stake in shares of Bicara Therapeutics during the third quarter worth about $177,169,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Bicara Therapeutics during the third quarter worth $1,420,000.

Analyst Ratings Changes

BCAX has been the topic of a number of recent analyst reports. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price target on the stock. HC Wainwright began coverage on Bicara Therapeutics in a research note on Friday, December 6th. They issued a “buy” rating and a $42.00 price objective for the company. TD Cowen started coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Finally, Cantor Fitzgerald began coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $43.00.

Bicara Therapeutics Stock Performance

BCAX opened at $15.25 on Friday. Bicara Therapeutics Inc. has a 52-week low of $15.15 and a 52-week high of $28.09. The company’s 50 day simple moving average is $19.64.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.